Trade VCYT anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Veracyte, Inc. (VCYT) is trading at US$43.34, down 4.22% today as of Aug 28, 16:00 EDT. The company has a market capitalisation of US$3.4B. Over the past 52 weeks, VCYT has traded between US$29.38 and US$60.91. On Syfe you can trade VCYT with $0 commission and add it to your watchlist.
| Previous close | US$45.25 |
|---|---|
| Market cap | US$3.4B |
| P/E ratio | 22.38 |
| 52-week range | US$29.38 – US$60.91 |
| Volume | 1.68M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Veracyte, Inc.
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
Year: 2013
Veracyte, Inc. (VCYT) stock is trading at US$43.34, -4.22% from the previous close of US$45.25.
The market cap for Veracyte, Inc. (VCYT) stock is approximately US$3.4B.
The price-to-earnings ratio for Veracyte, Inc. (VCYT) is 22.38, based on the latest reported earnings.
The 52-week high for Veracyte, Inc. (VCYT) stock is US$60.91.
The 52-week low for Veracyte, Inc. (VCYT) stock is US$29.38.
Veracyte, Inc. (VCYT) does not currently pay a dividend.
Stay on top of VCYT
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
